Clinical manifestations and treatment of drug-induced hepatotoxicity

Clinics in Liver Disease

Volumn 17, Issue 4, 2013, Pages 565-573

  Giordano, Christin M ^a   Zervos, Xaralambos B ^b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

Drug induced cholestasis; Drug induced hepatocellular injury; Drug induced liver injury; Management of drug induced liver injury

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; URSODEOXYCHOLIC ACID;

AUTOIMMUNITY; DIET SUPPLEMENTATION; FULMINANT HEPATIC FAILURE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERSENSITIVITY; LIVER CELL; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; MUSHROOM POISONING; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

DRUG-INDUCED CHOLESTASIS; DRUG-INDUCED HEPATOCELLULAR INJURY; DRUG-INDUCED LIVER INJURY; MANAGEMENT OF DRUG-INDUCED LIVER INJURY;

DRUG-INDUCED LIVER INJURY; HUMANS;

EID: 84884980471     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.07.003     Document Type: Review

References (45)

1. Zimmerman H. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott, Williams &Wilkins, Philadelphia. 2nd edition.
2. Dienstag J. Toxic and drug-induced hepatitis. Harrison's principles of internal medicine 2011, McGraw-Hill, New York, Available at, Accessed March 20, 2013. http://accessmedicine.com/content.aspx?aid=9134024, 18th edition. D. Longo, A. Fauci, D.L. Kasper (Eds.).
3. Lee W., Senior J. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005, 33:155-164.
4. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001, 24:483-490.
5. Chang C.Y., Schiano T.D. Review article: drug hepatoxicity. Aliment Pharmacol Ther 2007, 25:1135-1151.
6. Bjornsson E., Olsson R. Outcome and prognostic markers in severe-drug induced liver disease. Hepatology 2005, 42:481-489.
7. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954.
8. Vuppalanchi R., Liangpunsakul S., Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol 2007, 102:558-562.
9. Sembera S., Lammert C., Talwalkar J., et al. Frequency, clinical presentation and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl 2012, 18:803-810.
10. Farrell G.C. Liver disease caused by drugs, anesthetics, and toxins. Gastrointenstinal and liver disease 2002, 1403-1447. WB Saunders, Philadelphia. 7th edition. M. Feldman, L.S. Friedman, M.H. Sleisenger (Eds.).
11. Suk K.T., Kim D.J. Drug-induced liver injury: present and future. Clin Mol Hepatol 2012, 18:249-257.
12. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
13. Meier Y., Cavallaro M., Roos M., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005, 61:135-143.
14. de Abajo F.J., Montero D., Madurga M., et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004, 58:71-80.
15. Bjornsson E., Kalaitzakis E., Klinteberg V., et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007, 26:79-85.
16. De Valle M.B., Klinteberg V., Alem N., et al. Drug-induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006, 24:1187-1195.
17. Lammert C., Bjornsson E., Niklasson A., et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51:615-620.
18. Watkins P.B., Seeff L.B. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006, 43:618-631.
19. Aragon G., Younossi Z. When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med 2010, 77(3):195-204.
20. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. JHepatol 1990, 11:272-276.
21. Schomaker S., Warner R., Bock J., et al. Assessment of emerging biomarkers of liver injury in human subjects. Toxicol Sci 2013, 132(2):276-283.
22. Green R.M., Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002, 123(4):1367-1384.
23. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89(6):806-815.
24. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006, 15(4):241-243.
25. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
26. Bell L.N., Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009, 29:337-347.
27. Lucena M.I., Andrade R.J., Kaplowitz N., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender. Hepatology 2009, 49:2001-2009.
28. Food and Drug Administration Website. "Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation." Available at:. Accessed March 20, 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf.
29. Lucena M.I., Camargo R., Andrade R., et al. Comparison of two clinical scales for causality assessment in hepatoxicity. Hepatology 2001, 33(1):123-130.
30. Rochon J., Protiva P., Seef L., et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008, 48(4):1175-1183.
31. Watanabe M., Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. Hepatol Res 2004, 30:148-154.
32. Takikawa H., Takamori Y., Kumagi T., et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res 2003, 27:192-195.
33. Pichler W.J., Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004, 59(8):809-820.
34. Merk H.F. Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines. Toxicology 2005, 209(2):217-220.
35. Maria V., Victorino R. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997, 26(3):664-669.
36. Nathwani R.A., Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006, 10:207-217.
37. European Association for the Study of the Liver EASL clinical practice guidelines: management of cholestatic liver diseases. JHepatol 2009, 51:237-267.
38. Patel T., Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010, 11(10):1673-1682.
39. Czaja A. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011, 56:958-976.
40. Kanter M. Comparison of oral and IV acetylcysteine in the treatment of acetaminophen poisoning. Am J Health Syst Pharm 2006, 63(19):1821-1827.
41. Mengs U., Pohl R., Mitchell T. Legalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol 2012, 13(10):1964-1970.
42. Ward J., Kapadia K., Brush E., et al. Amatoxin poisoning: case reports and review of current therapies. JEmerg Med 2013, 44(1):116-121.
43. Magdalan J., Piotrowska A., Gomułkiewicz A., et al. Influence of commonly used clinical antidotes on antioxidant systems in human hepatocyte culture intoxicate with alpha-amanitin. Hum Exp Toxicol 2011, 30(1):38-43.
44. Organ Procurement and Transplantation Network. Policy 3.6. Available at:. Accessed March 20, 2013. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf.
45. Lee W.M., Hynan L.S., Rosaro L., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137(3):856-864.